Apollomics, Inc. (NASDAQ:APLM – Get Free Report) was the target of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 2,790,000 shares, a growth of 607.0% from the July 31st total of 394,600 shares. Currently, 4.2% of the shares of the company are sold short. Based on an average trading volume of 3,890,000 shares, the days-to-cover ratio is currently 0.7 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their price target on Apollomics from $5.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.
View Our Latest Stock Report on APLM
Institutional Inflows and Outflows
Apollomics Stock Performance
Shares of NASDAQ APLM opened at $0.13 on Wednesday. Apollomics has a twelve month low of $0.12 and a twelve month high of $5.00. The business has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.39.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Read More
- Five stocks we like better than Apollomics
- What is a Dividend King?
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- What Investors Need to Know About Upcoming IPOs
- Brinker International Offers a Pullback Opportunity on EPS Miss
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.